Date: December 16, 2019
Indies Pharma Jamaica Limited (INDIES), reported revenues for the twelve months ended October 31, 2019 of $725.90 million, an increase of 14% when compared with the $636.17 million booked last year. Revenues for the fourth quarter decreased 20% to $150.09 million (2018: $186.90 million).
Cost of sales amounted to a total of $223.68 million relative to the $243.38 million reported for the same period last year, an 8% decrease year over year.
As such, gross profit increased 28% or $109.43 million to a total of $502.22 million relative to the $392.79 million for the FY2018. Gross profit for the quarter closed at $115.21 million (2018: $104.16 million).
Other operating income for the year ended amounted to $710,400 a decline of 13% from last year’s $813,221.
Administrative expenses jumped up by 56% to close the period at $372.13 million (2018: $238.61 million). The company also noted that, “goods valuing approximately 46 million expired during the twelve-month period ending October 2019.”
This led to a dip in the company’s profit from operations from $154.99 million in 2018 to $130.80 million of this year. Profit from operations for the quarter closed at $19.16 million relative to $47.03 million recorded for the same quarter of 2018.
Notably, INDIES reported $4.71 million in foreign exchange gains for FY2019 (2018 foreign exchange losses: $4.48 million), while ‘finance cost- loan interest’ fell to $196,728 (2018: $11.27 million).
INDIES reported a profit before tax of $135.31 million relative to the $139.24 million reported in 2018.
Consequently, net profit for the year increased 13% to $135.31 million relative to a net profit $119.70 million in 2018, there was no tax charge for 2019, compared to $19.54 million in 2018. For the fourth quarter, net profit was $22.22 million (2018: $37.61 million)
Total comprehensive income totalled $140.46 million relative to $119.70 million in 2018, a 17% increase.
Earnings per share (EPS) for the period amounted $0.10 compared to and (EPS) of $0.09 recorded in 2018. For the quarter, EPS totalled $0.02 (2018: $0.03). The number of shares used in the calculations is 1,332,536,649. The stock last traded on December 13, 2019 at $3.24.
Balance Sheet at a glance:
As at October 31, 2019, total assets amounted to $778.54 million, 9% less than $851.26 million the year prior. This was as a result of a decline in ‘Related companies’ which closed $7.58 million (2018: $198.61 million). This decline was tempered by the increase in ‘Receivables’ which closed at $292.31 million (2018: $266.41 million), as well as a growth in “Property, plant and equipment” to $137.13 million (2018: $92.42 million).
Shareholders’ Equity totalled $702.50 million (2018: $668.64 million) resulting in a book value per share of $0.53 (2018: $0.50).
Management noted that, “the company remains debt free, which indicates its good financial health and shows that it is in a good position for future growth.”
Analyst Certification -The views expressed in this research report accurately reflect the personal views of Mayberry Investments Limited Research Department about those issuer (s) or securities as at the date of this report. Each research analyst (s) also certify that no part of their compensation was, is, or will be, directly or indirectly, related to the specific recommendation (s) or view (s) expressed by that research analyst in this research report.
Company Disclosure -The information contained herein has been obtained from sources believed to be reliable, however its accuracy and completeness cannot be guaranteed. You are hereby notified that any disclosure, copying, distribution or taking any action in reliance on the contents of this information is strictly prohibited and may be unlawful. Mayberry may effect transactions or have positions in securities mentioned herein. In addition, employees of Mayberry may have positions and effect transactions in the securities mentioned herein.
